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Kosaku Nitta1*, Norio Hanafusa2 and Ken Tsuchiya2Abstract
Chronic kidney disease-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism. In
patients undergoing peritoneal dialysis (PD), serum levels of calcium (Ca), phosphate (P), and parathyroid hormone
(PTH) remain relatively constant, irrespective of the timing of treatment. This is because PD is a continuous blood
purification procedure, and in this respect differs greatly from hemodialysis (HD), where the serum levels of these
factors change following each dialysis session, and so pre-dialysis values are considered baseline values.
Nevertheless, the target values for serum P, Ca, and PTH in PD patients are the same as those in HD patients. In PD
patients, however, it is plausible to initiate correction of any of these values once any tendency towards worsening
is observed, even if they are still within the upper limit of normal for HD patients. Restriction of dietary P intake,
conservation of residual renal function for excretion of P, and prescription of an appropriate P binder are
recommended to maintain the blood P level in the appropriate range. The use of a 2.5-mEq/L Ca concentration
dialysate reduces the risk of hypercalcemia and allows correction of adynamic bone disease. Meanwhile, secondary
hyperparathyroidism may progress in such cases. It is thus recommended that this factor be considered in
prescribing this type of dialysate.
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Chronic kidney disease-mineral bone disorder (CKD-
MBD) is a systemic condition that manifests as abnor-
malities in parathyroid hormone (PTH), calcium (Ca),
phosphorus (P), and vitamin D metabolism, with associ-
ated bone abnormalities and ectopic calcification [1]; it
is a major complication in patients undergoing periton-
eal dialysis (PD) [2]. CKD-MBD is associated with vascu-
lar calcification and cardiovascular disease (CVD), and
these conditions are closely related to an increased mor-
tality rate [3]. Guidelines for the treatment of
CKD-MBD have been published by Disease Outcomes
Quality Initiative (DOQI) [4] and Kidney Disease: Im-
proving Global Outcomes (KDIGO) [5]. Clinical practice
guideline for the management of CKD-MBD for Japa-
nese dialysis patients was recently published and was
made applicable to Japanese PD patients [6]. At the end
of 2015, the number of PD patients in Japan was 9322,* Correspondence: knitta@twmu.ac.jp
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CKD-MBD has led to the identification of clinical bio-
chemistry targeted to be achieved to improve the out-
come of PD patients. The purpose of this paper was to
review the literature concerning the management of
CKD-MBD in PD patients.Assessment of serum levels of Ca, P, and PTH
Abnormalities in serum Ca and P levels are independent
risk factors influencing survival prognosis in PD patients.
A Dutch prospective survey revealed a significant in-
crease in the risk of CVD-related death in PD patients
with a serum P level of ≥ 5.5 mg/dL and serum Ca×P
product of ≥ 55 [8]. Blood purification via PD involves
continuous, slow dialysis as compared with hemodialysis
(HD). Therefore, blood levels of Ca, P, and PTH remain
relatively constant in PD patients. In HD patients who
have marked fluctuations in serum Ca and P levels, the
pre-dialysis serum Ca and P levels, determined at the be-
ginning of the week when the patients’ condition is poor
due to the weekend break, are usually taken as a base-
line. In PD patients, if serum Ca, P, and PTH levelsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ered the patients’ status at all times. Ultimately, if any
value in a PD patient deviates from the baseline values,
intervention should be initiated promptly, with further
investigation and close monitoring of changes in serum
Ca, P, and PTH levels over time. According to the Dutch
survey [8], the risk of death from CVD due to hyperpho-
sphatemia was significantly higher for P concentrations
above the K/DOQI threshold in PD patients (2.4-fold)
and in HD patients (1.5-fold), suggesting the importance
of strict mineral management in PD patients. Percentage
achievement of the K/DOQI guideline for CKD-MBD
markers is based on plasma concentrations at 3 months
after the start of dialysis treatment in the Dutch survey
(Fig. 1).
Dialysis dose and metabolism of Ca and P
In PD patients, transperitoneal removal of P is at a rate
of approximately 200 to 300 mg per day, so it is difficult
to maintain appropriate serum P levels using PD alone.
It is thus important in such cases to restrict dietary P in-
take to conserve residual renal function for P excretionFig. 1 Percent achievement of the K/DOQI guideline for CKD-MBD, based
treatment [8]. In PD patients, 29% had plasma Ca level within the target ra
range of plasma P levels. The Ca×P target was reached by 58% of the PD p
concentrations below the target range, and 22% of the PD patients met thand to then prescribe an appropriate P binder. PD uti-
lizes a biomembrane and is dependent on residual renal
function with regard to solute removal; therefore, the
dialysis dose tends to decline over time as a result of the
diminution of peritoneal function and deterioration of
residual renal function [9]. If serum P level deteriorates,
therefore, it should be ascertained that the dialysis dose
is still adequate. PD dose is determined in terms of the
dialysis adequacy indicated by urea Kt/V per week
(weekly Kt/V). The dialysis dose may be assessed as sat-
isfactory when the Kt/V is ≥ 1.8 and should be main-
tained at a minimum of 1.7 as combined with residual
renal function [10–12]. Theoretically, patient survival
and morbidity have a dose-dependent relationship with
small-solute clearance (Fig. 2) [11]. Meanwhile, excessive
Ca loading due to the use of Ca-based P binders may
lead to vascular calcification and calciphylaxis, stressing
the need for precautions against the development of
hypercalcemia [13–16]. It is also important to exercise
great caution when using drugs such as sevelamer
hydrochloride [17, 18], lanthanum carbonate [19, 20],
and cinacalcet hydrochloride [21], which are liable toon plasma concentrations at 3 months after the start of dialysis
nge advised by K/DOQI. Conversely, 50% of the PD patients met the
atients. More than half of the patients had plasma intact PTH
e intact PTH target
Fig. 2 A hypothetical dose-dependent relationship with small-solute clearance in PD patients [11]. Theoretically, patient survival and mortality have a
dose-dependent relationship with small-solute clearance. Several cohort studies found that a higher dialysis dose was associated with better patient
survival and fewer hospitalizations. Based on the results of those studies, DOQI Workgroup recommended a total weekly Kt/V of 2.0 as target for
adequate PD.
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gastrointestinal obstruction. According to previous re-
ports, abdominal symptoms occurred in 18% of patients
receiving sevelamer hydrochloride and 16% of patients
receiving lanthanum carbonate. Peritoneal calcification
seen in PD patients may reflect vascular calcification
and mineral metabolic disorders. However, in most in-
stances, this is not associated with these disorders but
reflects advanced impairment of peritoneal tissues [22].
Adynamic bone disease in PD patients
Adynamic bone disease (ABD) resulting from low serum
levels of PTH is now recognized as a common complica-
tion in PD patients [23]. Carmen Sánchez et al. reported
that ABD was found in 63.2% of PD patients and that
PTH levels less than 150 pg/mL in patients with ABD
showed a sensitivity of 91.6% and specificity of 95.2%
[24]. Moreover, de Oliveira et al. have recently shown
that sclerostin, a Wnt/β-catenin pathway inhibitor that
decreases osteoblast action and bone formation, seems
to participate in the pathophysiology of ABD, and bone
alkaline phosphatase was the sensitive serum marker of
bone turnover in these patients [25].This condition depends mainly on the Ca concentra-
tion in the dialysate and the use of active vitamin D
preparations, and at present, there are no known bone
lesions peculiar to PD patients. Initially, PD fluids simply
contained positive Ca dialysates with a Ca concentration
of 3.5 mEq/L. Then, in 1990, a low Ca concentration di-
alysate with a negative Ca balance (2.5 mEq/L) was in-
troduced. This type of dialysate was produced with the
aim of enabling sufficient use of Ca carbonate and active
vitamin D preparations while avoiding serum Ca eleva-
tion. The current dialysate has a Ca concentration of 2.5
mEq/L and is used from the initial phase of PD. As a
result, the incidence of hypercalcemia and low bone
turnover have both decreased compared with that in
cases where dialysates with a Ca concentration of 3.5
mEq/L are used, but the incidence of high bone turnover
due to serum PTH elevation has been increasing [26,
27]. In a cross-sectional observational study conducted
in Japan, comparison of patient groups receiving dialysis
with a 3.5-mEq/L or 2.5-mEq/L Ca concentration dialys-
ate, stratified according to the duration of dialysis, re-
vealed that the proportion of patients receiving Ca
carbonate and active vitamin D preparations was higher
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tended to be higher in the low-Ca dialysate group,
despite the absence of any significant intergroup dif-
ference in serum Ca or P levels (Fig. 3) [28]. These
results underscore the importance of Ca and PTH
management from the early phase of PD and suggest
that adjustment of the Ca concentration in the dialys-
ate should precede pharmacotherapy in terms of the
order of priority of treatment.
With this background, the use of a dialysate with a Ca
concentration of 3.5-mEq/L should be considered,
particularly in order to avoid hypocalcemia in the intro-
ductory phase of dialysis. Prescription of a dialysate with
a Ca concentration corresponding to the serum level in
each patient undergoing PD is feasible, unlike with HD
where the access is via the central vein. Mineral manage-
ment should therefore take advantage of the characteris-
tics of PD, in which personalized therapy is readily
practicable. For example, the efficacy of cinacalcet for
secondary hyperparathyroidism during the maintenance
phase has been also demonstrated in PD patients [29].
Vascular calcification in PD patients
Abdominal aortic calcification (AAC) has been reported
as a predictor for CVD events in HD patients. Martino
et al. were the first to show the predictive value of AAC
for the outcomes in PD patients (Fig. 4) [30]. A total of
74 Italian PD patients were followed for a median of
30.5 months, during which there were 29 CVD events
(39.2%). In multivariable regression analysis, AAC score
stratified by tertiles was the only independent predictorFig. 3 Changes in serum calcium (S-Ca) and serum phosphorus (S-Pi) in th
The percentages of SCD, LCD, and the combination of SCD and LCD were
the time of the survey. These findings show that LCD is a convenient mean
CaCO3 and vitamin D analogsfor CVD events. Also, Makela et al. recently shown
that severe AAC was a strong predictor of all-cause
mortality and CVD events in PD patients, while PD
patients with normal AAC scores had more favorable
outcomes [31]. Older age, low serum albumin level,
and diabetes were also independently associated with
increased all-cause mortality. Risk stratification by as-
sessment of AAC score may provide important infor-
mation for the management of CVD in PD patients
without any additional expense because these patients
undergo several abdominal X-ray scans to evaluate
the catheter position.
The most important methods for the prevention and
treatment of vascular calcification are dietary P restric-
tion and adequate use of P binders for hyperphosphate-
mia. The severe vascular calcification associated with
hyperphosphatemia is a result of the phenotypic conver-
sion of smooth muscle cells to osteoblasts [32]. The
KDOQI recommends a target of P < 5.5 mg/dL, while
KDIGO recommends normalization. There are several
commercially available P binders that are invariably
equally effective. These can either be Ca-containing (Ca
carbonate, Ca acetate) or Ca-free (sevelamer hydrochlor-
ide, lanthanum carbonate, magnesium carbonate). Fur-
thermore, the iron-containing P binder such as ferric
citrate hydrate and sucroferric oxyhydroxide has recently
been marketed.
Hypomagnesemia has also been found to be associated
with increased mortality in PD patients [33]. Molnar et al.
have recently shown that lower serum magnesium is asso-
ciated with vascular calcification in PD patients [34].e low-Ca dialysate (LCD) and standard-Ca dialysate (SCD) groups [28].
respectively 49%, 50%, and 1% at initiation and 40%, 38%, and 22% at
s of producing sufficient serum reserve to increase the doses of
Fig. 4 Relationship between aortic abdominal calcification (AAC) score and cardiovascular (CV) events [30]. Patients with high AAC score (third
tertile) had significantly higher risk of CV events, in comparison with those with lower AAC score (log rank P < 0.001)
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lar calcification in PD patients with hypomagnesemia.
Conclusions
PD is a continuous blood purification procedure and dif-
fers greatly from HD, where the serum Ca, P, and PTH
levels change following each dialysis session, and
pre-dialysis values are taken as the baseline values.
Nevertheless, the target values for these factors in PD
patients are the same as those in HD patients. In PD pa-
tients, however, it is plausible to initiate correction of
any of these values once any tendency towards worsen-
ing is observed, even if they are still within the upper
limit of normal for HD patients. Restriction of dietary P
intake, conservation of residual renal function for excre-
tion of P, and prescription of an appropriate P binder are
all recommended to maintain the blood P level in the
appropriate range. The use of a 2.5-mEq/L Ca concen-
tration dialysate reduces the risk of hypercalcemia and
allows correction of ABD.
Future perspectives
Future research in this field will shed light on several
topics, including a comparison of CKD-MBD manage-
ment across different countries and the relationship
between dialysate Ca concentrations and vascular calcifi-
cation in PD patients. These studies should be designed to
overcome several weaknesses in the literature, such as a
lack of information on gender, ethnicity, and prescription
of P binders such as magnesium carbonate, all of whichmay influence the grade of vascular calcification and
osteoporosis. In addition, high-glucose PD solution may
lead to low-turnover bone, and further studies are needed
to explore whether it is true or not. Moreover, continuous
renal replacement therapy may be associated with a
change in bone metabolism or vascular calcification.
While a loss of circadian rhythm is a characteristic of sec-
ondary hyperparathyroidism, a continuous replacement
therapy will affect the PTH level. Updated clinical practice
guideline for the management of CKD-MBD in Japanese
dialysis patients will be published in the near future.
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